Biography for Emily Mullin
Emily Mullin, Associate Editor
Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at [email protected] and follow her on Twitter at @EmilyMFierce.
- Contact Emily
- Follow Emily on Google+
Articles by Emily Mullin
AstraZeneca inks deal with Advaxis for immunotherapy-vaccine combo trial
AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.
Germany's immatics bags $30M for cancer vaccine trial
Though the cancer vaccine field has seen more setbacks than successes, some companies are forging ahead with ambitious plans to push their therapeutics toward regulatory approval.
Extra dose of inactivated polio vaccine provides greater protection in children
As polio flare-ups in central Asia, the Middle East and Central Africa continue, a new study suggests that an extra dose of the inactivated polio vaccine could further protect children under 5 years old in high-risk countries.
U.S. bioterror readiness highlighted after NIH smallpox discovery
The discovery of vials of "variola," commonly known as smallpox, in a storage room at the National Institutes of Health in Bethesda, MD, has raised new concerns that the virus could be used in a bioterrorism attack.
Ongoing Ebola outbreak sparks debate on experimental vaccine testing
International debate is brewing over whether to give experimental vaccines to people in regions of the current Ebola outbreak in West Africa in an effort to thwart the spread of the deadly virus.
Novartis starts shipping Flucelvax ahead of upcoming flu season
Novartis has started shipping vaccines for customers in the U.S. in advance of the next flu season, which doesn't include a quadrivalent offering like many of its competitors. But the shipments will include Flucelvax, which now has an FDA-licensed American plant that's poised for production whenever flu shots are needed.
Agenus brain cancer vaccine boosts survival in PhII trial
Patients with a lethal form of brain cancer lived nearly twice as long as expected after receiving Agenus' ($AGEN) Prophage vaccine in a Phase II study, according to the company.
Reuters: Sanofi plans to put dengue program into separate unit
Sanofi has been working on a vaccine to protect against the mosquito-borne dengue virus for 20 years, and now it may be breaking that program off into a distinct unit.
CDC committee recommends AZ's FluMist over flu shot in children
AstraZeneca's flu vaccine sales may have just gotten a boost, courtesy of federal regulators. Wednesday, they recommended that healthy children 2 to 8 years old receive the company's nasal spray flu vaccine FluMist in lieu of flu shots when available.
Northwest Bio begins German vax trial as glioblastoma market poised to double
With the expected launch of Northwest Biotherapeutics' dendritic cell-based therapeutic vaccine DCVax-L, the glioblastoma multiforme drug market is expected to grow rapidly, from $305 million in 2012 to $583 million in 2019, according to market research.
